Filing Summary
Entity and period: The supplied filing is Jupiter Wellness, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2022—not a BONK, Inc. filing as indicated in the request metadata. The summary below reflects the filing text provided.
Business context and reporting period
Jupiter Wellness develops CBD-based wellness and therapeutic products and, through subsidiary SRM Entertainment, sells merchandise to theme parks and entertainment venues. The company describes its CBD product and clinical pipeline as early stage. Figures below are in U.S. dollars.
Financial performance and position
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Revenue | $721,629 | $48,846 |
| Cost of sales | $604,418 | $23,452 |
| Gross profit and margin | $117,211; 16.2% | $25,394; 52.0% |
| Net loss | $2,919,775 | $2,195,763 |
| Basic and diluted loss per share | $0.13 | $0.20 |
| Net cash used in operating activities | $2,712,872 | $1,254,376 |
| Cash at period end | $6,145,558 | $11,754,558 at Dec. 31, 2021 |
Revenue growth was mainly from SRM, which contributed $707,105 versus no reported revenue in Q1 2021; Jupiter Wellness’s segment revenue was $14,524. Gross margin contracted substantially. The net loss included a $1 million impairment of the additional NFP note advance. General and administrative expense was $1,978,933, including $105,000 of stock compensation; R&D expense was $103,025.
At March 31, total assets were $13,295,270, total liabilities $1,640,793, and shareholders’ equity $11,654,477. Current assets were $10,809,044 and current liabilities $1,019,925. The balance sheet reports no convertible notes payable and $47,981 outstanding on the SBA loan; lease liabilities totaled $785,038. The company also disclosed $198,324 outstanding on financing for insurance premiums.
Cash decreased by $5,609,000 during the quarter. The cash-flow statement reports $1,934,843 used in investing activities and $961,285 used in financing activities, but the section labels appear reversed or inconsistent with the listed transactions; verify against the filed statements.
Changes, outlook, risks, and unusual items
- Compared with Q1 2021, revenue increased sharply, but gross margin fell and net loss widened. The prior-year comparison included $1,682,913 of stock compensation and a $669,200 gain on settlement of an acquisition-related note, versus $105,000 of stock compensation and a $1 million note impairment in Q1 2022.
- The company said 2021 revenue had been depressed by COVID-19 and that demand was improving. It provided no quantified financial guidance or specific revenue outlook.
- NFP terminated the proposed acquisition transaction. After issuing a default notice, the company impaired the additional $1 million funded in January 2022. The filing says the original $10 million note was impaired against 2021 earnings.
- After quarter-end, the company entered into two convertible notes totaling $2 million, due October 20, 2022, bearing 8% interest and issued with 5% original issue discounts. Related warrants cover 1.46 million shares in total, with a $2.79 exercise price.
- The company repurchased 1,995,948 shares for $2,133,167 through March 31, 2022. It reported 22,150,053 shares issued and outstanding at quarter-end; 21,901,528 were outstanding as of May 10, 2022. Additional repurchases after quarter-end were disclosed.
- A federal lawsuit remained pending, with an unjust-enrichment counterclaim against the company and its CEO; trial was scheduled to begin no earlier than November 14, 2022. The company seeks damages in its own complaint. Management said it was unaware of other pending or threatened litigation expected to materially affect financial position, results, or liquidity.
- Nasdaq had identified a listing-rule issue concerning consultant share grants; the company reported remedial actions and said Nasdaq confirmed compliance and closed the matter in January 2022. Management stated disclosure controls were effective and described remediation of previously disclosed internal-control weaknesses.
- Key business risks include early-stage product development, clinical and FDA-related uncertainty, dependence on purchase orders rather than long-term SRM customer agreements, and continued operating cash outflows. The company cautioned that forward-looking statements are subject to risks and actual results may differ.
Important facts for investors to verify
- Confirm the intended issuer: the provided filing is for Jupiter Wellness, Inc. (ticker JUPW), not BONK, Inc.
- Reconcile the cash-flow statement’s investing and financing subtotals and labels to the underlying transactions.
- Review the status, recoverability, and legal enforcement of the NFP notes and the accounting for the $1 million Q1 impairment.
- Assess post-quarter financing terms, maturity, potential dilution from the notes and warrants, and liquidity relative to ongoing cash burn.
- Track SRM customer orders and margins, the pending litigation, and progress and regulatory requirements for the CBD product pipeline.